辅助刺激领域影响了B细胞恶性瘤中CD19 CAR-T细胞耐药性的发展
Marta Krawczyk1,2,3, Narcis Fernandez-Fuentes4, Klaudyna Fidyt2,4
1Department of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
bioRxiv : the preprint server for biology
|March 17, 2025
概括
针对B细胞恶性瘤的CAR-T疗法表现出耐药性,通常是由于CD19抗原损失. 这项研究揭示了4-1BBCAR-T细胞驱动CD19突变,与CD28CAR-T细胞不同,影响治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 针对CD19的化学抗原受体T细胞 (CAR-T) 治疗是B细胞恶性瘤复发/耐药的关键治疗方法.
- 治疗耐药性和复发发生在大约一半的患者中,需要了解潜在的耐药性机制.
- CAR-T细胞共刺激域的差异 (例如,CD28与4-1BB) 可能会影响治疗疗效和耐药性.
研究的目的:
- 研究B细胞恶性瘤中CD19-CAR-T细胞耐药性的机制.
- 为了比较基于CD28的CD19-CAR-T细胞与基于4-1BB的CD19-CAR-T细胞对抗原损失和治疗反应的影响.
- 阐明CD19突变和抗原表达水平在CAR-T耐药性中的作用.
主要方法:
- 在体外共培B细胞淋巴瘤/白血病与表达CD19-CAR-T细胞的CD28或4-1BB共刺激域的B细胞淋巴瘤/白血病模型.
- 对CD19抗原表达的分析,包括总蛋白质水平和特定表位的识别 (FMC63).
- 使用测序识别CD19中的遗传突变.
- 数学建模和in silico模拟分析CAR-T细胞对抗不同抗原表达的瘤的活动.
主要成果:
- 具有4-1BB共刺激域的CD19-CAR-T细胞诱导了CD19抗原损失 (包括总蛋白和FMC63表位) 并与CD19突变 (框架转移/误解) 相关.
- 具有CD28共刺激域的CD19-CAR-T细胞没有驱动抗原逃逸.
- 数学模拟表明,对抗低抗原表达瘤细胞的CAR-T细胞活性差异有助于异质反应,4-1BB CAR-T细胞可能无法消除这些细胞,从而促进耐药性.
结论:
- 造价刺激域选择显著影响CD19-CAR-T细胞抵抗机制,4-1BB域促进抗原损失和突变,与CD28域不同.
- 这些发现为基于CD28 (axicabtagene ciloleucel) 和基于4-1BB (tisagenlecleucel) 的CD19-CAR-T治疗B细胞淋巴瘤之间观察到的临床差异提供了机制性的见解.
- 精确检测FMC63表位是评估CD19-CAR-T细胞可访问的抗原水平和预测治疗结果的关键.
相关概念视频
B Cell Activation and Differentiation
1.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.4K
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
T Cell Activation and Clonal Selection
620
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
620
Cytotoxic T Cells-mediated Immune Response
823
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
823
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


